Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Post DEAL Interview
View:
Post by 24minus7 on Jun 14, 2022 5:54am

Post DEAL Interview

https://57ea05b9-8ae7-4fa0-b2d8-87d70d135d8c.usrfiles.com/ugd/57ea05_e067cb96589a468c806b109903079c43.pdf Lets talk numbers. Can you elaborate on the actual figures? HV: Do you see this smile on my face? I can assure everyone that AbbVie is rewarding Sirona Biochem appropriately for our breakthrough technology. Although I am contractually bound to not comment on how much we are receiving, suffice it to say that it will be substantial given that we are getting royalty payments on the global sales of AbbVies products based on our patents. AbbVie has an agreement that allows them to commercialize and market TFC-1067 worldwide into their established global network.
Comment by sakinny3 on Jun 14, 2022 7:13am
very interesting read. Slide 8 has numbers to chew on. 40 million usd royalties annually is the target
Comment by sakinny3 on Jun 14, 2022 7:16am
clearly these last slides are PRC doing their own guesstimate but helps gauge what could be out there
Comment by Pareto8020 on Jun 14, 2022 7:20am
So they do a company making deal and don't release any numbers so the market or anyone can evaulate it?  R you f'n kidding me??!!! "Let’s talk numbers. Can you elaborate on the actual figures? HV: Do you see this smile on my face? I can assure everyone that AbbVie is rewarding Sirona Biochem appropriately for our breakthrough technology. Although I am contractually bound to not ...more  
Comment by navajojoe on Jun 14, 2022 7:47am
This post has been removed in accordance with Community Policy
Comment by lscfa on Jun 14, 2022 7:49am
Zero visibility on dollar amounts and timing.   Mgmt's talk about buying equipment and hiring suggests maybe a $2 million upfront payment.    R+F took 18 months to launch after signing a deal.  I doubt Skinmedica is any faster.   
Comment by navajojoe on Jun 14, 2022 8:01am
This post has been removed in accordance with Community Policy
Comment by sakinny3 on Jun 14, 2022 8:08am
You have to remember that when we signed with R+F we didn't even have a company to manufacture the 1067 active ingredient, that took quite some time to set up as well adding to the timeline
Comment by biorun on Jun 14, 2022 8:04am
This is now moving from a company selling proven interest on one or two research experiments to a company positioned to do what we always said it should try to be. There is so much to feed the imagination here. 1. Acceleration Finally- Between the mysterious upfront payment and the french government significant support to keep additional grants rolling in, there is zero worry for cash from now on ...more  
Comment by Transperance on Jun 14, 2022 8:54am
Bio, I have a question related to item 3. Is there a need for Phase 1 type testing for Anti-Aging? The scope/extent of clinical trial for Anti-Aging should agree with that for TFC-1067, should it not? Both compounds are for Cosmetic use. Further, I don’t understand why there is a need for Sirona to invite big pharma in the Anti-Aging clinical trial process. Such a third-party would have the ...more  
Comment by navajojoe on Jun 14, 2022 9:00am
This post has been removed in accordance with Community Policy
Comment by biorun on Jun 14, 2022 9:15am
How do we know they aren't? Anyone could be there.
Comment by biorun on Jun 14, 2022 9:12am
It depends upon what they are seeking to do with the anti-aging formula. If its to wipe out the need to use Botox, then maybe it needs a trial process. If it is a supplement to existing treatments, maybe not.
Comment by Pandora on Jun 14, 2022 10:44am
So at 10x current value of 24 cents you are suggesting $2.40. Any guess at a time frame to get to above $2?
Comment by biorun on Jun 14, 2022 10:52am
as soon as the market wakes up and new investors come on board. we should ideally see some serious share price movements this month. Howards job #1. He has everything to show the world how great this is. It is great. 
Comment by Pareto8020 on Jun 14, 2022 11:09am
No institution or even a retail crowd is going to start piling into this and driving the shareprice up until some numbers are made public and they can financially translate that into an equivalent share price.  Just isn't going to happen and the paltry increase in the share price in reaction to this epic deal is proof.  Nobody is taking Howard's word/smile or PRC's estimate ...more  
Comment by navajojoe on Jun 14, 2022 11:41am
This post has been removed in accordance with Community Policy
Comment by navajojoe on Jun 14, 2022 11:07am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities